Form 4: Eli Casdin Reports Acquisition of Standard BioTools Stock via Restricted Stock Units

Eli Casdin, a director and 10% owner of Standard BioTools Inc., reports acquiring 1,588 shares of common stock through Restricted Stock Units (RSUs) in lieu of cash compensation.

Summary

• On July 19, 2024, Eli Casdin acquired 1,588 shares of Standard BioTools Inc. common stock through Restricted Stock Units (RSUs).
• These RSUs were granted in lieu of $3,750 in cash compensation for his services as a board member.
• The RSUs vest as to 25% on July 23, 2024, and then in two equal installments on the 15th day of the last month of each remaining fiscal quarter of 2024, contingent upon continued service.
• Following the transaction, Casdin directly owns 2,752,332 shares.
• Casdin also indirectly owns a significant number of shares through various funds, including Casdin Private Growth Equity Fund II, L.P. (13,939,637 shares), Casdin Private Growth Equity Fund, L.P. (2,744,219 shares), Casdin Partners Master Fund, L.P (46,730,821 shares), and Casdin Amplify Fund, LP (545,000 shares).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing an insider transaction. The acquisition of shares by a director could be interpreted slightly positively, but it's primarily a procedural disclosure.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future.

Future Outlook

The vesting schedule of the RSUs extends into the remaining fiscal quarters of 2024, contingent on continued service.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the ownership changes of key personnel.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a director.

Key Dates